Connect with us

TechCrunch

FindAir is a smart inhaler

FindAir is digitizing asthma therapy with smart inhaler technology. The TC Top Picks program showcases outstanding early-stage startups across these categories: AI/Machine Learning, Biotech/Healthtech, Blockchain, Fintech, Mobility, Privacy/Security, Retail/E-commerce, Robotics/IoT/Hardware, SaaS and Social Impact & Education. TechCrunch is a leading technology media property, dedicated to obsessively profiling startups, reviewing new Internet products, and breaking tech…

Published

on

FindAir is digitizing asthma therapy with smart inhaler technology.

The TC Top Picks program showcases outstanding early-stage startups across these categories: AI/Machine Learning, Biotech/Healthtech, Blockchain, Fintech, Mobility, Privacy/Security, Retail/E-commerce, Robotics/IoT/Hardware, SaaS and Social Impact & Education.

TechCrunch is a leading technology media property, dedicated to obsessively profiling startups, reviewing new Internet products, and breaking tech news.

Continue Reading
Advertisement
9 Comments

9 Comments

  1. Abhishek Rao Chimbili

    October 27, 2019 at 4:51 pm

    That is the most useless thing I’ve ever seen.

  2. Brandon S.

    October 27, 2019 at 4:52 pm

    You are supposed to use a spacer. The inhaler alone is not good. Not to mention there are some inhalers that already track the number of uses. This is pointless.

  3. Greg Nulik

    October 27, 2019 at 7:21 pm

    Hope the sensor supports a full dosage.

  4. polyannamoonbeam

    October 27, 2019 at 10:39 pm

    Not enough info …sensor tells you what your trigger was…? How? Blood prick analysis? Heartrate? Allergen analysis? Doctors are now instructed to ration patients to one Ventolin a month, two if you argue at length. There is no science to back up patients self diagnosed need for more, doctors differ on what is sufficient, how to measure severity and are often punitive/ biased against smokers. Many patients become resistant to their Ventolyn due to misuse, long term use.. tracking usage doesnt tell you whether patient needed to use more or less puffs for each event or just misused due to poor technique….severe attacks are not managed by Ventolin. Steroids,adrenalin, intravenous meds, full mask vaporised meds- we use all in winter for son.

  5. Pinitrius

    October 27, 2019 at 11:34 pm

    Being an allergist I was interested to see what this was about… But no! It gives some information about patient adherence to the treatment but as with many products/service it is trying to force a subscription down patients throat without providing real long term value! And the product itself is rendered useless after 12 months due to the non-removable battery!

    To me it is just a gimmick the way they chose to make it and charge for it! Sorry…

  6. TechPimp

    October 28, 2019 at 1:51 am

    I didn’t understand what the heck it does?

  7. Gezaei Teklay

    October 28, 2019 at 2:09 am

    I hope it is helpful for asthma

  8. Arthur

    October 28, 2019 at 9:12 am

    So it counts how many times you use an inhaler a day and displays it on an app?

  9. takeonparis

    October 29, 2019 at 12:15 am

    This is the dumbest interview I’ve ever seen. He doesn’t even bother to ask: “So what does your product DO?” Like what in the actual hell…

Leave a Reply

Your email address will not be published. Required fields are marked *

Science & Technology

Google just broke SEO. Here’s what replaces it. | Equity Podcast

Google I/O made it official: AI-generated answers are now front and center in search, and most brands have almost no visibility into how AI is describing them to their customers. For anyone who has spent years building a strategy around 10 blue links, the rules just changed in a pretty significant way. On this episode…

Published

on

Google I/O made it official: AI-generated answers are now front and center in search, and most brands have almost no visibility into how AI is describing them to their customers. For anyone who has spent years building a strategy around 10 blue links, the rules just changed in a pretty significant way.

On this episode of TechCrunch’s Equity podcast, Rebecca Bellan caught up with Matt Thompson, VP of partnerships at Scrunch, a startup positioning itself at the center of the AI search shift, to talk about what Google’s changes mean and marketers and founders should actually do about it.

Subscribe to Equity on YouTube, Apple Podcasts, Overcast, Spotify and all the casts. You also can follow Equity on X and Threads, at @EquityPod.

Chapters

00:00 Intro

01:15 Why Google is going all-in on AI search

03:25 Meet Scrunch

09:00 Personalized agents, shopping, and Google’s advantage

12:13 What advertisers need to track now

13:48 How websites become “agent ready”

15:34 AI search vs. traditional SEO

22:33 “Scrunching” webpages down for AI agents

23:47 Google’s SEO guidance vs. Scrunch’s approach

27:17 Why unique human content still matters

28:51 Advice for startups adapting to AI search

29:52 Outro

Continue Reading

Science & Technology

SpaceX’s S-1 Claims a TAM as Large as the Annual US GDP

The SpaceX S-1 dropped, and the $28 trillion TAM claim inside is somehow not even the wildest part. The Equity podcast team breaks down what’s in the filing, and whether any of this math connects to reality.

Published

on

The SpaceX S-1 dropped, and the $28 trillion TAM claim inside is somehow not even the wildest part.

The Equity podcast team breaks down what’s in the filing, and whether any of this math connects to reality.

Continue Reading

Science & Technology

SpaceX files to go public, and the math requires a little faith | Equity Podcast

The SpaceX S-1 is finally here, and the story it tells goes way further than rockets. The filing runs to 36 pages of risk factors alone, and the numbers inside match the ambition: a $28 trillion total addressable market, a pay package tied to establishing a Mars colony, and a valuation target that would make…

Published

on

The SpaceX S-1 is finally here, and the story it tells goes way further than rockets. The filing runs to 36 pages of risk factors alone, and the numbers inside match the ambition: a $28 trillion total addressable market, a pay package tied to establishing a Mars colony, and a valuation target that would make it the largest IPO in American history.

On this episode of TechCrunch’s Equity podcast, Kirsten Korosec, Anthony Ha, and Sean O’Kane dig into the week’s biggest talent shakeups, acquisitions, and headlines — including what the filing actually says and whether any of this math connects to reality.

Subscribe to Equity on YouTube, Apple Podcasts, Overcast, Spotify and all the casts. You also can follow Equity on X and Threads, at @EquityPod.

Chapters:

00:00 Intro

3:28 NanoCo raises $12M seed for secure OpenClaw alternative

9:46 Anthropic acquires Stainless and hires Andrej Karpathy

15:12 The consumer backlash against AI being pushed by big tech

16:37 Google Search as you know it is changing as AI takes over

22:14 SpaceX’s S-1 is here

27:54 Is the $1.75 trillion valuation justified?

32:47 Outro

Continue Reading

Trending